Larimar Therapeutics (ZA71) Price & Analysis

3 Followers

ZA71 Stock Chart & Stats

€4.04

€0.04(1.08%)

At close: Jan 08 4:00 PM EST

€4.04

€0.04(1.08%)

Day’s Range― - ―

52-Week Range€2.36 - €5.25

Previous CloseN/A

Volume0.00

Average Volume (3M)610.00

Market Cap

€357.57M

Enterprise Value€209.55

Total Cash (Recent Filing)€200.38M

Total Debt (Recent Filing)€3.78M

Price to Earnings (P/E)―

Beta0.67

Next Earnings

Aug 06, 2026

EPS Estimate

-0.33

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.10

Shares Outstanding103,882,935

10 Day Avg. Volume300

30 Day Avg. Volume610

Financial Highlights & Ratios

PEG Ratio-0.02

Price to Book (P/B)3.56

Price to Sales (P/S)0.00

P/FCF Ratio-2.45

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€10.93

Price Target Upside170.45% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

EPS Forecast (FY)-1.41

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage / Conservative Balance SheetReported total debt of roughly $3.8M and a ~0.02 debt-to-equity ratio indicate low financial leverage. This durable strength reduces solvency and interest-rate risk, giving management more strategic flexibility to prioritize clinical programs or raise capital on less onerous terms.

Regulatory Pathway Advancing (rolling BLA)Submission of the first rolling BLA module and FDA alignment on a surrogate endpoint materially de-risks the approval pathway. Over the next 2-6 months this structural regulatory progress can shorten development timelines and increase the probability of accelerated approval for a first-in-class therapy.

Supportive Clinical Biomarker And Functional SignalsDurable biomarker increases (skin frataxin to 18 months) plus directional functional improvements across 43 dosed patients strengthen the scientific rationale. These consistent signals improve regulatory, clinician, and payer confidence in nomlabofusp's disease-modifying potential, boosting long-term commercialization odds.

Bears Say

Pre-revenue Operating ProfileLarimar remains a pre-revenue biotech with no commercial products, meaning it cannot self-fund operations from sales. This persistent lack of operating revenue creates ongoing dependency on external financing and increases execution risk as programs scale toward potential commercialization.

Accelerating Cash BurnOperating cash outflows have accelerated materially to roughly -$131.3M TTM, up markedly from prior years. This structural cash consumption shortens runway and elevates the probability of near-term financings, increasing dilution risk and constraining discretionary investment choices.

Authorized Share Expansion Increases Dilution RiskApproval to nearly double authorized shares provides management flexibility to raise capital but creates a durable overhang: the enlarged share pool makes future equity issuance easier, raising the structural risk of meaningful dilution for existing holders when funding clinical advancement.

Larimar Therapeutics News

Closing Bell Movers: Levi Strauss down 6% on earnings

Investors bought the early-session dip in the Tech space on Wednesday, helping the sector join Energy as the...

15d ago

AZZ

Larimar Therapeutics director buys $167K in common stock

In a regulatory filing, Larimar Therapeutics (LRMR) disclosed that its director, Thomas Hamilton, bought 50,000 shares of common...

15d ago

LRMR

Citizens biotech analysts hold an analyst/industry conference call

Biotech Analysts discuss Friedreich’s Ataxia developments from the patient community perspective (relevant companies LRMR SLDB BIIB PTCT LXEO...

21d ago

BIIB

DSGN

Larimar Therapeutics assumed with a Buy at H.C. Wainwright

H.C. Wainwright assumed coverage of Larimar Therapeutics (LRMR) with a Buy rating and $10 price target The company’s...

22d ago

LRMR

Larimar Therapeutics price target lowered to $5 from $7 at Baird

Baird analyst Christopher Chen lowered the firm’s price target on Larimar Therapeutics (LRMR) to $5 from $7 and...

24d ago

LRMR

Larimar Therapeutics selloff a buying opportunity, says Citi

Citi recommends buying Larimar Therapeutics (LRMR) shares on yesterday’s weakness. FDA feedback indicates the company’s current data package...

24d ago

LRMR

Midday Fly By: SpaceX to join Nasdaq-100, Comcast to split into two companies

The major averages were broadly higher near noon as investors await news out of the Middle East after...

24d ago

CRM

Larimar stumbles on safety news even as BLA submission kicks off

Larimar Therapeutics (LRMR) shares slid on Monday after the company reported new safety findings from its open label...

24d ago

LRMR

Larimar Therapeutics submits first module of rolling BLA for nomlabofusp

Larimar Therapeutics (LRMR) announced it has submitted the first module of its rolling Biologics License Application submission to...

25d ago

LRMR

Buy Rating Reaffirmed on Growing Nomlabofusp Confidence; $25 Price Target Maintained

Analyst Francois Brisebois from LifeSci Capital maintained a Buy rating on Larimar Therapeutics and keeping the price target...

2d ago

LRMR

Larimar, Cytokinetics, Itau, Global-e, Immunovant Shake-Up

Insiders have been trading these 5 stocks: (($LRMR)), (($CYTK)), (($ITUB)), (($GLBE)) and (($IMVT)). Here is a breakdown of...

13d ago

CYTK

GLBE

Adobe, Larimar, Palantir, Chevron, eXp Trending With Analysts

Analysts are intrested in these 5 stocks: ( ($ADBE) ), ( ($LRMR) ), ( ($PLTR) ), ( ($CVX)...

20d ago

CVX

ADBE

Larimar Therapeutics: Buy Rating on Nomlabofusp’s Robust FA Efficacy and De-Risked Regulatory Pathway

William Blair analyst Myles Minter has reiterated their bullish stance on LRMR stock, giving a Buy rating today....

24d ago

LRMR

Nomlabofusp Progress and Durable Efficacy Support Buy Rating on LRMR with Unchanged $25 Price Target

In a report released today, Francois Brisebois from LifeSci Capital maintained a Buy rating on Larimar Therapeutics, with...

24d ago

LRMR

ZA71 FAQ

What was Larimar Therapeutics, Inc.’s price range in the past 12 months?

Larimar Therapeutics, Inc. lowest stock price was €2.36 and its highest was €5.25 in the past 12 months.

What is Larimar Therapeutics, Inc.’s market cap?

Larimar Therapeutics, Inc.’s market cap is €357.57M.

When is Larimar Therapeutics, Inc.’s upcoming earnings report date?

Larimar Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 13 days.

How were Larimar Therapeutics, Inc.’s earnings last quarter?

Larimar Therapeutics, Inc. released its earnings results on May 14, 2026. The company reported -€0.272 earnings per share for the quarter, beating the consensus estimate of -€0.469 by €0.197.

Is Larimar Therapeutics, Inc. overvalued?

According to Wall Street analysts Larimar Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Larimar Therapeutics, Inc. pay dividends?

Larimar Therapeutics, Inc. does not currently pay dividends.

What is Larimar Therapeutics, Inc.’s EPS estimate?

Larimar Therapeutics, Inc.’s EPS estimate is -0.33.

How many shares outstanding does Larimar Therapeutics, Inc. have?

Larimar Therapeutics, Inc. has 103,882,935 shares outstanding.

What happened to Larimar Therapeutics, Inc.’s price movement after its last earnings report?

Larimar Therapeutics, Inc. reported an EPS of -€0.272 in its last earnings report, beating expectations of -€0.469. Following the earnings report the stock price went down -1.149%.

Which hedge fund is a major shareholder of Larimar Therapeutics, Inc.?

Currently, no hedge funds are holding shares in DE:ZA71

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Larimar Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

22.53%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Larimar Therapeutics, Inc.

Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.

Larimar Therapeutics (ZA71) Earnings & Revenues

Historic Earnings Reports

ZA71 Stock 12 Month Forecast

Average Price Target

€10.93

▲(170.45% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"€1","22":"€22","6.25":"€6.25","11.5":"€11.5","16.75":"€16.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":21.852612,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€21.85</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.926305999999999,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€10.93</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.3705224,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€4.37</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,6.25,11.5,16.75,22],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.6,4.080970153846154,5.561940307692307,7.042910461538462,8.523880615384615,10.004850769230769,11.485820923076922,12.966791076923075,14.44776123076923,15.928731384615384,17.409701538461537,18.89067169230769,20.371641846153846,{"y":21.852612,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.6,3.240485076923077,3.880970153846154,4.521455230769231,5.161940307692308,5.802425384615384,6.442910461538462,7.083395538461538,7.723880615384616,8.364365692307691,9.004850769230769,9.645335846153845,10.285820923076923,{"y":10.926305999999999,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.6,2.736194030769231,2.8723880615384614,3.0085820923076922,3.144776123076923,3.2809701538461535,3.4171641846153844,3.5533582153846153,3.6895522461538457,3.8257462769230766,3.9619403076923074,4.098134338461538,4.234328369230768,{"y":4.3705224,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.4,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.98,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.1,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.86,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.48,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.98,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.32,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.9,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.26,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.82,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.62,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.6,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >